Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 19027483

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2008 Nov 22
First author
Kim ES

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2008 Nov 22;372(9652):1785-6. doi: 10.1016/S0140-6736(08)61741-9.
    note
    Source null
    related pmid
    19027472
    relationship
    Comment in
  2. citation
    Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60193-8.
    note
    Source null
    related pmid
    19217979
    relationship
    Comment in
  3. citation
    Lancet. 2009 Feb 14;373(9663):541-2; author reply 542. doi: 10.1016/S0140-6736(09)60194-X.
    note
    Source null
    related pmid
    19217980
    relationship
    Comment in
  4. citation
    Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6.
    note
    Source null
    related pmid
    19217981
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2009 Oct 1;27(28):e128-9; author reply e130-1. doi: 10.1200/JCO.2009.22.8049.
    note
    Source null
    related pmid
    19720902
    relationship
    Comment in

Authors and identifiers

  1. name
    Kim ES
    type
    Author
  2. name
    Hirsh V
    type
    Author
  3. name
    Mok T
    type
    Author
  4. name
    Socinski MA
    type
    Author
  5. name
    Gervais R
    type
    Author
  6. name
    Wu YL
    type
    Author
  7. name
    Li LY
    type
    Author
  8. name
    Watkins CL
    type
    Author
  9. name
    Sellers MV
    type
    Author
  10. name
    Lowe ES
    type
    Author
  11. name
    Sun Y
    type
    Author
  12. name
    Liao ML
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kim ES
    type
    Author
  2. name
    Hirsh V
    type
    Author
  3. name
    Mok T
    type
    Author
  4. name
    Socinski MA
    type
    Author
  5. name
    Gervais R
    type
    Author
  6. name
    Wu YL
    type
    Author
  7. name
    Li LY
    type
    Author
  8. name
    Watkins CL
    type
    Author
  9. name
    Sellers MV
    type
    Author
  10. name
    Lowe ES
    type
    Author
  11. name
    Sun Y
    type
    Author
  12. name
    Liao ML
    type
    Author
bibliography ids
  1. nci-bib-99241731b59ce7f3109f5ac8
book metadata
content sha256
b25ef8057a03f241a4a334212336bc195ad650006ad434a5019bc3dd4587c8b1
document type
citation
dois
  1. 10.1016/S0140-6736(08)61758-4
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:19027483
immutable id
pubmed:19027483@b25ef8057a03f241a4a334212336bc195ad650006ad434a5019bc3dd4587c8b1
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9652
name
Lancet (London, England)
nlm unique id
2985213R
pages
1809-18
volume
372
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2008 Nov 22;372(9652):1785-6. doi: 10.1016/S0140-6736(08)61741-9.
    note
    Source null
    related pmid
    19027472
    relationship
    Comment in
  2. citation
    Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60193-8.
    note
    Source null
    related pmid
    19217979
    relationship
    Comment in
  3. citation
    Lancet. 2009 Feb 14;373(9663):541-2; author reply 542. doi: 10.1016/S0140-6736(09)60194-X.
    note
    Source null
    related pmid
    19217980
    relationship
    Comment in
  4. citation
    Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6.
    note
    Source null
    related pmid
    19217981
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2009 Oct 1;27(28):e128-9; author reply e130-1. doi: 10.1200/JCO.2009.22.8049.
    note
    Source null
    related pmid
    19720902
    relationship
    Comment in
outcomes validated
false
pmid
19027483
provenance
batch id
27a383f06e5fc3d04fad
provider
NCBI PubMed ESummary
record sha256
f6913bf958652542bbe737f3605559262138b1c916930f6886fcdb5fef1196cf
response sha256
51f0f2a142dbd9b135e872b049b116f51941299445a5416feae10f12fac8d978
retrieved at
2026-09-09T23:46:24.265787+00:00
publication date
display
2008 Nov 22
precision
day
year
2008
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/19027483/
title
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Preserved source evidence · Not medical advice